Participants exposed critical gaps in the diagnosis, treatment, and coordination of care for patients with heart failure with preserved ejection fraction and charted a path forward.

The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

LONDON — The benefit of mineralocorticoid receptor antagonists (MRAs) for the treatment of patients with heart failure and mildly reduced or preserved ejection fraction has finally been established in ...

Among patients with heart failure with preserved ejection fraction (HFpEF), lower versus higher ranges of EF signal fundamentally different morphologies and hemodynamic responses, which may have ...

Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target ...

Heart failure (HF) substantially impacts the health and financial security of an increasing proportion of the US population. It worsens debility and quality of life and may lead to hospitalization and ...

Data from London and Wuhan, China show first-phase ejection fraction, a measure of preclinical heart failure, to be the strongest predictor of survival in COVID-19. (Hypertension) Healthcare workers ...

Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ...